Literature DB >> 25222343

Sorting an LDL receptor with bound PCSK9 to intracellular degradation.

Trond P Leren1.   

Abstract

OBJECTIVE: This article reviews the mechanism by which the low density lipoprotein receptor (LDLR) that has bound proprotein convertase subtilisin/kexin type 9 (PCSK9), is rerouted to intracellular degradation instead of being recycled.
METHODS: A search of relevant published literature has been conducted.
RESULTS: PCSK9 binds to the LDLR at the cell surface. It is the catalytic domain of PCSK9 that binds to the epidermal growth factor repeat A of the LDLR. The LDLR:PCSK9 complex is internalized through clathrin-mediated endocytosis. Due to an additional electrostatic interaction at acidic pH between the C-terminal domain of PCSK9 and the ligand-binding domain of the LDLR, PCSK9 remains bound to the LDLR in the sorting endosome. As a consequence, the LDLR fails to adopt a closed conformation and is degraded instead of being recycled. The mechanism for the failure of the LDLR to recycle appears to involve ectodomain cleavage of the extended LDLR by a cysteine cathepsin in the sorting endosome. The cleaved LDLR ectodomain will be confined to the vesicular part of the sorting endosome for degradation in the endosomal/lysosomal tract.
CONCLUSION: Ectodomain cleavage of an LDLR with bound PCSK9 in the sorting endosome disrupts the normal recycling of the LDLR.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cathepsin; Degradation; Endosome; LDL receptor; PCSK9

Mesh:

Substances:

Year:  2014        PMID: 25222343     DOI: 10.1016/j.atherosclerosis.2014.08.038

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  25 in total

1.  Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus.

Authors:  Constantine E Kosmas; Andreas Sourlas; Kyriaki V Bouza; Eddy DeJesus; Delia Silverio; Peter D Montan; Eliscer Guzman
Journal:  Ann Transl Med       Date:  2018-04

Review 2.  Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology.

Authors:  José Tuñón; Lina Badimón; Marie-Luce Bochaton-Piallat; Bertrand Cariou; Mat J Daemen; Jesus Egido; Paul C Evans; Imo E Hoefer; Daniel F J Ketelhuth; Esther Lutgens; Christian M Matter; Claudia Monaco; Sabine Steffens; Erik Stroes; Cécile Vindis; Christian Weber; Magnus Bäck
Journal:  Cardiovasc Res       Date:  2019-01-01       Impact factor: 10.787

Review 3.  PCSK9 inhibitors - mechanisms of action.

Authors:  Michael M Page; Gerald F Watts
Journal:  Aust Prescr       Date:  2016-10-01

4.  The enigmatic role of sortilin in lipoprotein metabolism.

Authors:  Charles E Sparks; Robert P Sparks; Janet D Sparks
Journal:  Curr Opin Lipidol       Date:  2015-12       Impact factor: 4.776

Review 5.  Sortilin, encoded by the cardiovascular risk gene SORT1, and its suggested functions in cardiovascular disease.

Authors:  Mads Kjolby; Morten Schallburg Nielsen; Claus Munck Petersen
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

6.  Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.

Authors:  Chutikarn Butkinaree; Maryssa Canuel; Rachid Essalmani; Steve Poirier; Suzanne Benjannet; Marie-Claude Asselin; Anna Roubtsova; Josée Hamelin; Jadwiga Marcinkiewicz; Ann Chamberland; Johann Guillemot; Gaétan Mayer; Sangram S Sisodia; Yves Jacob; Annik Prat; Nabil G Seidah
Journal:  J Biol Chem       Date:  2015-06-17       Impact factor: 5.157

7.  An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.

Authors:  Kévin Ly; Rachid Essalmani; Roxane Desjardins; Nabil G Seidah; Robert Day
Journal:  J Biol Chem       Date:  2016-10-07       Impact factor: 5.157

8.  Endocytic adaptors Arh and Dab2 control homeostasis of circulatory cholesterol.

Authors:  Wensi Tao; Robert Moore; Yue Meng; Elizabeth R Smith; Xiang-Xi Xu
Journal:  J Lipid Res       Date:  2016-03-22       Impact factor: 5.922

9.  Retinoschisis and Norrie disease: a missing link.

Authors:  Rahini Rajendran; Dhandayuthapani Sudha; Subbulakshmi Chidambaram; Hemavathy Nagarajan; Umashankar Vetrivel; Jayamuruga Pandian Arunachalam
Journal:  BMC Res Notes       Date:  2021-05-26

10.  LDL-Cholesterol-Lowering Therapy.

Authors:  Angela Pirillo; Giuseppe D Norata; Alberico L Catapano
Journal:  Handb Exp Pharmacol       Date:  2022
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.